standards will reduce the adverse environmental impacts associated with the discharges, stimulate the development of improved pollution control devices, and advance the development of environmentally sound ships by the Armed Forces.

CMP Project No: 16-1408-F2

FEDERAL AGENCY ACTIONS:

Applicant: ExxonMobil Corporation

Location: Outer Continental Shelf, Green Canyon Area Blocks 326, 327, and 471

Project Description: This initial exploration plan (EP/Plan) is for Green Canyon Blocks 326, 327 and 371, OCS-G 34977, 34978 & 34981 respectively. Exxon Mobil Corporation (ExxonMobil) plans to drill six new subsea wells, Wells A, B C, D, E and F. If the wells are successful they will be developed under a future Development Operations Coordination Document (DOCD). If a well is unsuccessful it will be plugged and abandoned in accordance with the Bureau of Safety and Environmental Enforcement (BSEE) regulations.

CMP Project No: 16-1410-F4

Pursuant to §306(d)(14) of the Coastal Zone Management Act of 1972 (16 U.S.C.A. §§1451 - 1464), as amended, interested parties are invited to submit comments on whether a proposed action or activity is or is not consistent with the Texas Coastal Management Program goals and policies and whether the action should be referred to the Land Commissioner for review.

Further information on the applications listed above, including a copy of the consistency certifications or consistency determinations for inspection, may be obtained from Mr. Jesse Solis, P.O. Box 12873, Austin, Texas 78711-2873, or via email at federal.consistency@glo.texas.gov. Comments should be sent to Mr. Solis at the above address or by email.

TRD-201604598
Anne L. Idsal
Chief Clerk, Deputy Land Commissioner
General Land Office
Filed: August 31, 2016

♦ ♦ ♦

Notice of Award of a Major Consulting Contract

Pursuant to Chapter 2254, Subchapter B, Texas Government Code, the Texas General Land Office ("GLO") announces the award of Contract No. 16-403-003 to Protection Development, Inc., an entity with a principal place of business at 8620 N. New Braunfels, San Antonio, Texas 78217. The contractor will assist with the evaluation of current and future construction and designs for compliance with applicable codes, laws, guidelines and best practices for design and construction projects for GLO's Office of Construction Services.

The total value of the contracts within the indefinite delivery indefinite quantity vendor pool is $200,000.00 for each fiscal year. The contract was executed on August 23, 2016, and will expire on August 31, 2017, unless extended or terminated sooner by the parties.

TRD-201604548
Anne L. Idsal
Chief Clerk, Deputy Land Commissioner
General Land Office
Filed: August 29, 2016

♦ ♦ ♦

Department of State Health Services

Amendment to the Texas Schedules of Controlled Substances

These amendments to the Texas Schedules of Controlled Substances were signed by the Commissioner of the Department of State Health Services, and will take effect 21 days following publication of this notice in the *Texas Register*.

The Administrator of the Drug Enforcement Administration (DEA) issued a final rule placing

(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropoyl)methanone (Other names: UR-144 and 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole), [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (Other names: 5-fluoro-UR-144 and 5-F-UR-144 and XLR11 and 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole); and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (Other names: APINACA and AKB48) including salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible, into Schedule I controlled substances in the federal schedules of controlled substances under the authority of the United States Controlled Substances Act May 11, 2016. This final order was published in the Federal Register, Volume 81, Number 91, pages 29142-29145. The substances were previously temporarily scheduled effective May 16, 2013. The Administrator has taken action based on the following.

1. UR-144, XLR-11 and APINACA have a high potential for abuse that is comparable to other schedule I substances such as delta-9-tetrahydrocannabinol and JWH-018;

2. UR-144, XLR-11 and APINACA have no currently accepted medical use in treatment in the United States; and

3. There is a lack of accepted safety for use of UR-144, XLR-11 and APINACA under medical supervision.

The Administrator of the Drug Enforcement Administration (DEA) issued a final order to temporarily schedule the synthetic opioids N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide (Other name: butyryl fentanyl) and N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylproprionamide, also known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidnyl]-N-phenylpropanamide (Other name: beta-hydroxythiofentanyl), and their isomers, esters, ethers, salts and salts of isomers, esters and ethers into Schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act effective May 12, 2016. This final order was published in the Federal Register, Volume 81, Number 92, pages 29492-29496. The Administrator has taken action based on the following:

1. Placement of butyryl fentanyl and beta-hydroxythiofentanyl into Schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety;

2. Butyryl fentanyl and beta-hydroxythiofentanyl have a high potential for abuse;

3. Butyryl fentanyl and beta-hydroxythiofentanyl have no currently accepted medical use in treatment in the United States; and,

4. Butyryl fentanyl and beta-hydroxythiofentanyl lack accepted safety for use under medical supervision.

The Administrator of the Drug Enforcement Administration (DEA) issued an interim final rule placing the substance brivaracetam ((2S0-2-[(4R0-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (Other names; BRV, UCB-34714, and Briviact) including its salts into Schedule V of the Controlled Substances Act effective May 12, 2016. This

interim final rule was published in the Federal Register, Volume 81, Number 92, pages 29487-29491. The Administrator has taken action based on the following:

1. Brivaracetam is a drug approved by the Department of Health and Human Services (HHS);

2. HHS recommended control under the Controlled Substances Act; and

3. Brivaracetam meets the eight-factor analysis pursuant to Title 21, United States Code, §811(b).

The Administrator of the Drug Enforcement Administration (DEA) issued a final order to place 3,4-dichloro-N-[(dimethylamino)cyclohexymethyl]benzamide) (Other name: AH-7921), including its isomers, esters, ethers, salts and salts of isomers, esters and ethers, into Schedule I pursuant the Controlled Substances Act effective May 16, 2016. This final order was published in the Federal Register, Volume 81, Number 72, pages 22023-22025. The Administrator has taken action based on the following:

1. The United States is required to control AH-7921 in order to meet the obligations of the Single Convention on Narcotic Drugs, 1961; and,

2. AH-7921 has no currently accepted medical use in the United States.

Pursuant to §481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Health and Safety Code, Chapter 481, at least thirty-one days have expired since notice of the above referenced actions were published in the Federal Register; and, in the capacity as Commissioner of the Texas Department of State Health Services, John Hellerstedt, M.D., does hereby order that the substances UR-144, XLR-11, APINACA and AH-7921 be placed into Schedule I; butyryl fentanyl and beta-hydroxythiofentanyl be placed into Schedule I temporarily scheduled substances; and, the substance brivaracetam be placed into Schedule V.

SCHEDULE I

Schedule I consists of:

- Schedule I opiates

The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts of isomers, esters, and ethers is possible within the specific chemical designation:

(1) Acetyl alpha methylfentanyl (N [1 (1 methyl 2 phenethyl) 4 piperidinyl] N phenylacetamide);

*(2) AH-7921 (3,4-dichloro-N-[(dimethylamino)cyclohexymethyl]benzamide))

(3) Allylprodine;

(4) Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

(5) Alpha methylfentanyl or any other derivative of Fentanyl;

(6) Alpha methylthiofentanyl (N [1 methyl 2 (2 thienyl) ethyl 4 piperidinyl] N- phenyl-propanamide);

(7) Benzethidine;

(8) Beta hydroxyfentanyl (N [1 (2 hydroxy 2 phenethyl) 4 piperidinyl] N phenyl-propanamide);

(9) Beta hydroxy 3 methylfentanyl (N [1 (2 hydroxy 2 phenethyl) 3 methyl 4 piperidinyl] N phenylpropanamide);

(10) Betaprodine;

(11) Clonitazene;

(12) Diampromide;

(13) Diethylthiambutene;

(14) Difenoxin;

(15) Dimenoxadol;

(16) Dimethylthiambutene;

(17) Dioxaphetyl butyrate;

(18) Dipipanone;

(19) Ethylmethylthiambutene;

(20) Etonitazene;

(21) Etoxeridine;

(22) Furethidine;

(23) Hydroxypethidine;

(24) Ketobemidone;

(25) Levophenacylmorphan;

(26) Meprodine;

(27) Methadol;

(28) 3 methylfentanyl (N [3 methyl 1 (2 phenylethyl) 4 piperidyl] N phenylpropanamide), its optical and geometric isomers;

(29) 3 methylthiofentanyl (N [3 methyl 1 (2 thienyl)ethyl 4 piperidinyl] N phenylpropanamide);

(30) Moramide;

(31) Morpheridine;

(32) MPPP (1 methyl 4 phenyl 4 propionoxypiperidine);

(33) Noracymethadol;

(34) Norlevorphanol;

(35) Normethadone;

(36) Norpipanone;

(37) Para fluorofentanyl (N (4 fluorophenyl) N [1 (2 phenethyl)-4 piperidinyl]-propanamide);

(38) PEPAP (1 (2 phenethyl) 4 phenyl 4 acetoxypiperidine);

(39) Phenadoxone;

(40) Phenampromide;

(41) Phencyclidine;

(42) Phenomorphan;

(43) Phenoperidine;

(44) Piritramide;

(45) Proheptazine;

(46) Properidine;

(47) Propiram;

(48) Thiofentanyl (N phenyl N [1 (2 thienyl)ethyl 4 piperidinyl] propanamide);

(49) Tilidine; and

(50) Trimeperidine.

- Schedule I opium derivatives

***

- Schedule I hallucinogenic substances

***

- Schedule I stimulants

***

- Schedule I depressants

***

- Schedule I Cannabimimetic agents

Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

(1) The term 'cannabimimetic agents' means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:

(1-1) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.

(1-2) 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.

(1-3) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.

(1-4) 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.

(1-5) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.

(2) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Other names: CP-47,497);

(3) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (Other names: cannabicyclohexanol or CP-47,497 C8 homolog);

(4) 1-pentyl-3-(1-naphthoyl)indole (Other names:JWH-018 and AM678);

(5) 1-mutyl-3-(1-naphthoyl)indole (Other names: JWH-073);

(6) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);

(7) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (Other names: JWH-200);

(8) 1-pentyl-3-(2-methoxyphenylacetyl)indole (Other names: JWH-250);

(9) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (Other names: JWH-081);

(10)1-pentyl-3-(4-methyl-1-naphthoyl)indole (Other names: JWH-122);

(11)1-pentyl-3-(4-chloro-1-naphthoyl)indole (Other names: JWH-398);

(12) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (Other names: AM2201);

(13) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (Other names: AM694);

(14) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (Other names: SR-19 and RCS-4);

(15) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (Other names: SR-18 and RCS-8);

(16) 1-pentyl-3-(2-chlorophenylacetyl)indole (Other names: JWH-203);

*(17) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other names: UR-144 and 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole);

*(18) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (Other names: 5-fluoro-UR-144 and 5-F-UR-144 and XLR11 and 1-(5-flouro-pentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole); and,

*(19) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (Other names: APINACA, AKB48).

- Schedule I temporarily listed substances subject to emergency scheduling by the United States Drug Enforcement Administration.

Unless specifically excepted or unless listed in another schedule, a material, compound, mixture, or preparation that contains any quantity of the following substances or that contains any of the substance's salts, isomers, esters, ethers and salts of isomers, esters and ethers if the existence of the salts, isomers, esters, ethers and salts of isomers is possible within the specific chemical designation.

1. 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);

2. 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names:25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);

3. 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (Other names:25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);

4. Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: PB-22; QUPIC);

5. Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5-fluoro-PB-22; 5F-PB-22);

6. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: AB-FUBINACA);

7. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: ADB-PINACA);

8. 4-methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one);

9. 4-methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names:

4-MePPP; MePPP; 4-methyl-[alpha]-pyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one);

10. alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one);

11. Butylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one);

12. Pentedrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one);

13. Pentylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one);

14. 4-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one);

15. 3-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one);

16. Naphyrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one);

17. alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one);

18. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (Other names: "B-CHMINACA");

19. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (Other names: "AB-PINACA");

20. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (Other names: "THJ-2201");

21. N-(1-phenethylpiperindin-4-yl)-N-phenylacetamide (Other names: acetyl fentanyl);

*22. N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide (Other name: butyryl fentanyl); and

*23. N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylproprionamide, also known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidnyl]-N-phenylpropanamide (Other name: beta-hydroxythiofentanyl).

SCHEDULE V

Schedule V consists of:

- Schedule V narcotics containing non-narcotic active medicinal ingredients

***

- Schedule V stimulants

***

- Schedule V depressants

Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible;

(*1) Brivaracetam ((2S0-2-[(4R0-2-oxo-4-propylpyrrolidin-1-yl]butanamide) (Other names; BRV, UCB-34714, and Briviact);

(2) Ezogabine;

(3) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-proprionamide]; and

(4) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].

Changes to the schedules are designated by an asterisk (*).

TRD-201604539
Lisa Hernandez
General Counsel
Department of State Health Services
Filed: August 29, 2016

♦ ♦ ♦

Licensing Actions for Radioactive Materials